The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of hear...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2017/9561405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563648000688128 |
|---|---|
| author | Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen |
| author_facet | Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen |
| author_sort | Vamsi C. Gaddipati |
| collection | DOAJ |
| description | Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms. |
| format | Article |
| id | doaj-art-90a3951d38584e5eab5d9ad62faad30c |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-90a3951d38584e5eab5d9ad62faad30c2025-02-03T01:12:59ZengWileyCase Reports in Cardiology2090-64042090-64122017-01-01201710.1155/2017/95614059561405The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated CardiomyopathyVamsi C. Gaddipati0Aarti A. Patel1Adam J. Cohen2Department of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USADepartment of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USADepartment of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USAPeripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms.http://dx.doi.org/10.1155/2017/9561405 |
| spellingShingle | Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy Case Reports in Cardiology |
| title | The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy |
| title_full | The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy |
| title_fullStr | The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy |
| title_full_unstemmed | The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy |
| title_short | The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy |
| title_sort | use of a novel heart failure agent in the treatment of pregnancy associated cardiomyopathy |
| url | http://dx.doi.org/10.1155/2017/9561405 |
| work_keys_str_mv | AT vamsicgaddipati theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT aartiapatel theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT adamjcohen theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT vamsicgaddipati useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT aartiapatel useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT adamjcohen useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy |